Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

被引：0
|
作者：
Ip, Andrew [1 ]
Munoz, Javier [2 ]
Rosenthal, Allison C. [3 ]
Darrah, Justin M. [4 ]
Wang, Tongsheng [5 ]
Zhang, Guihua [5 ]
Mutebi, Alex [6 ]
Jun, Monika [5 ]
Ding, Zhijie [5 ]
Chhibber, Anindit [6 ]
Navarro, Fernando Rivas [7 ]
Risum, Malene [7 ]
Atiya, Mohammad [6 ]
Brodkin, Samantha [5 ]
Wang, Anthony W. [8 ]
Alshreef, Abualbishr [8 ]
Harb, Diala [8 ]
Sacchi, Mariana [5 ]
Hoehn, Daniela
Karimi, Yasmin H. [9 ]
机构：
[1] Hackensack Univ, Hackensack Univ Med Ctr, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[4] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Cellular Therapy, Los Angeles, CA USA
[5] Genmab, Plainsboro, NJ USA
[6] Genmab US Inc, Plainsboro, NJ USA
[7] Genmab, Copenhagen, Denmark
[8] AbbVie Inc, N Chicago, IL USA
[9] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203540
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7757 / 7758
页数：2
相关论文
共 50 条
  • [1] Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis
    Munoz, Javier
    Rosenthal, Allison C.
    Ip, Andrew
    Darrah, Justin M.
    Wang, Tongsheng
    Zhang, Guihua
    Mutebi, Alex
    Jun, Monika
    Ding, Zhijie
    Chhibber, Anindit
    Navarro, Fernando Rivas
    Risum, Malene
    Atiya, Mohammad
    Brodkin, Samantha
    Wang, Anthony W.
    Alshreef, Abualbishr
    Harb, Diala
    Sacchi, Mariana
    Hoehn, Daniela
    Karimi, Yasmin H.
    BLOOD, 2024, 144 : 7760 - 7761
  • [2] A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Hertzberg, Mark
    Ku, Matthew
    Catalani, Olivier
    Althaus, Betsy
    Simko, Stephen
    Gregory, Gareth P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant
    Fox, David
    El Moustaid, Fadoua
    Masaquel, Anthony
    Rosettie, Katherine L.
    Celik, Hazal
    Cassoli, Lourenia
    Flowers, Christopher R.
    BLOOD, 2024, 144 : 5027 - 5028
  • [4] Azacytidine plus rituximab-gemcitabine-oxaliplatin as salvage treatment in patients with relapsed/ refractory diffuse large B-cell lymphoma
    Meng Fanqiao
    Xiang Maoyuan
    Peng Cuicui
    Liu Yu
    Zeng Dongfeng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S453 - S453
  • [5] Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Castro, Felipe
    Surinach, Andy
    Launonen, Aino
    Thuresson, Per-Olof
    Felizzi, Federico
    BLOOD, 2020, 136
  • [6] Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
    Gaetano Corazzelli
    Gaetana Capobianco
    Manuela Arcamone
    Pier Ferruccio Ballerini
    Emilio Iannitto
    Filippo Russo
    Ferdinando Frigeri
    Cristina Becchimanzi
    Gianpaolo Marcacci
    Annarosaria De Chiara
    Antonio Pinto
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 907 - 916
  • [7] Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
    Corazzelli, Gaetano
    Capobianco, Gaetana
    Arcamone, Manuela
    Ballerini, Pier Ferruccio
    Iannitto, Emilio
    Russo, Filippo
    Frigeri, Ferdinando
    Becchimanzi, Cristina
    Marcacci, Gianpaolo
    De Chiara, Annarosaria
    Pinto, Antonio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) : 907 - 916
  • [8] Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study
    Cai, Qingqing
    Zhou, Hui
    Li, Zhiming
    Li, Wenyu
    Wu, Yudan
    Wu, Bingyi
    Yang, Hui
    Liang, Stephen Yang
    Su, Ning
    Liu, Panpan
    Zhang, Xuanye
    Xia, Yi
    Ma, Shuyun
    BLOOD, 2020, 136
  • [9] Subcutaneous Epcoritamab With Gemcitabine plus Oxaliplatin (GemOx) Induced High Response Rates in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT)
    Brody, Joshua
    Wahlin, Bjorn E.
    Phillips, Tycel
    Costello, Regis
    Lugtenburg, Pieternella
    Cordoba, Raul
    Wang, Liwei
    Wu, Jun
    Elliott, Brian
    Abbas, Aqeel
    Jorgensen, Judit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S379 - S380
  • [10] POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hirata, Jamie
    Perretti, Thomas
    Musick, Lisa
    McMillan, Andrew K.
    BLOOD, 2021, 138
12345